FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239529837> ?p ?o ?g. }

• W4239529837 abstract "Prior guidelines stated that trypanocidal therapy should not be used for treating chronic asymptomatic Trypanosoma cruzi infections. However, the recent availability of clinical trials reporting high rates of parasitologic cure in children with early chronic T. cruzi infection have produced changes of these recommendations in some countries. Because of the uncertainty regarding best treatment for this stage of T. cruzi infections, the literature was reviewed systematically for a synthesis of the available evidence.To assess the effects of trypanocidal therapy for chronic asymptomatic T. cruzi infection.We searched The Cochrane Controlled Trials Register (Issue 1, 2000), MEDLINE (start-Nov 1999), EMBASE (start - Feb 2000), LILACS (start - Feb 2000) and the Tropical Diseases Research Division of WHO database (Start - Feb 2000). Reference lists of articles were searched for relevant material.Published RCTs of trypanocidal therapy for people with chronic, asymptomatic T. cruzi infectionsTwo reviewers independently screened papers for inclusion criteria, quality assessment and data extraction. Forms were used to collect data. Reviewers resolved differences by discussion then a third reviewer if necessary.Of 43 papers assessed for inclusion, five RCTs (total population=756) met the inclusion criteria. The quality of the trials was rated as low (n=3) or intermediate (n=2). Two RCTs tested benznidazole in school children and three tested different agents in adults. The Odds Ratios and their 95%CI (Fixed models) were: Incidence of ECG abnormalities: 0.41 (0.09, 1.85); Negative seroconversion (AT ELISA): 10.91 (6.07, 19.58); Negative xenodiagnosis during the follow up: 5.37 (3.34, 8.64); Standardised mean reduction of antibody titres: 0.54 (0.31, 0.84). Nitroimidazolic derivatives substantially and significantly modified parasite-related outcomes compared to placebo. Other agents showed borderline or not significant effect.Despite major public health importance, trypanocidal.therapy for chronic asymptomatic T. cruzi infection has been tested in few, small size RCTs which were designed to assess parasitic-related, but not clinical outcomes. Therefore, the potential of trypanocidal therapy to prevent Chagas' disease among asymptomatic, chronically infected subjects is promising, but remains to be evaluated. trypanocidal therapy, particularly nitroimidazolic derivatives given to children or adults with positive xenodiagnosis improve parasite-related outcomes. The large contrast between the burden of Chagas disease and the existing evidence on its prevention points the need to test these or newer agents in more and larger RCTs that include clinical endpoints." @default.
• W4239529837 created "2022-05-12" @default.
• W4239529837 creator A5018419311 @default.
• W4239529837 creator A5040857289 @default.
• W4239529837 creator A5047557715 @default.
• W4239529837 creator A5060634423 @default.
• W4239529837 creator A5070145871 @default.
• W4239529837 date "2002-01-21" @default.
• W4239529837 modified "2023-10-16" @default.
• W4239529837 title "Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection" @default.
• W4239529837 cites W1436216279 @default.
• W4239529837 cites W1964999278 @default.
• W4239529837 cites W1966953116 @default.
• W4239529837 cites W1968599630 @default.
• W4239529837 cites W1968838681 @default.
• W4239529837 cites W1976835046 @default.
• W4239529837 cites W1980807216 @default.
• W4239529837 cites W1986215651 @default.
• W4239529837 cites W1989875914 @default.
• W4239529837 cites W1995600978 @default.
• W4239529837 cites W2005029486 @default.
• W4239529837 cites W2019982027 @default.
• W4239529837 cites W2020628060 @default.
• W4239529837 cites W2033451677 @default.
• W4239529837 cites W2042974171 @default.
• W4239529837 cites W2044153901 @default.
• W4239529837 cites W2049102964 @default.
• W4239529837 cites W2062092686 @default.
• W4239529837 cites W2066805289 @default.
• W4239529837 cites W2071316624 @default.
• W4239529837 cites W2072102507 @default.
• W4239529837 cites W2099494169 @default.
• W4239529837 cites W21134292 @default.
• W4239529837 cites W2113628732 @default.
• W4239529837 cites W2139287872 @default.
• W4239529837 cites W2141990013 @default.
• W4239529837 cites W2186154522 @default.
• W4239529837 cites W2243701891 @default.
• W4239529837 cites W2333642805 @default.
• W4239529837 cites W2417396513 @default.
• W4239529837 doi "https://doi.org/10.1002/14651858.cd003463" @default.
• W4239529837 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11869663" @default.
• W4239529837 hasPublicationYear "2002" @default.
• W4239529837 type Work @default.
• W4239529837 citedByCount "29" @default.
• W4239529837 countsByYear W42395298372012 @default.
• W4239529837 countsByYear W42395298372013 @default.
• W4239529837 countsByYear W42395298372014 @default.
• W4239529837 countsByYear W42395298372015 @default.
• W4239529837 countsByYear W42395298372016 @default.
• W4239529837 countsByYear W42395298372017 @default.
• W4239529837 countsByYear W42395298372019 @default.
• W4239529837 countsByYear W42395298372020 @default.
• W4239529837 crossrefType "reference-entry" @default.
• W4239529837 hasAuthorship W4239529837A5018419311 @default.
• W4239529837 hasAuthorship W4239529837A5040857289 @default.
• W4239529837 hasAuthorship W4239529837A5047557715 @default.
• W4239529837 hasAuthorship W4239529837A5060634423 @default.
• W4239529837 hasAuthorship W4239529837A5070145871 @default.
• W4239529837 hasBestOaLocation W42395298372 @default.
• W4239529837 hasConcept C126322002 @default.
• W4239529837 hasConcept C136764020 @default.
• W4239529837 hasConcept C156957248 @default.
• W4239529837 hasConcept C17744445 @default.
• W4239529837 hasConcept C187212893 @default.
• W4239529837 hasConcept C199539241 @default.
• W4239529837 hasConcept C2776171842 @default.
• W4239529837 hasConcept C2777625466 @default.
• W4239529837 hasConcept C2777910003 @default.
• W4239529837 hasConcept C2778335811 @default.
• W4239529837 hasConcept C2779473830 @default.
• W4239529837 hasConcept C2781049234 @default.
• W4239529837 hasConcept C2908647359 @default.
• W4239529837 hasConcept C41008148 @default.
• W4239529837 hasConcept C535046627 @default.
• W4239529837 hasConcept C71924100 @default.
• W4239529837 hasConcept C71928629 @default.
• W4239529837 hasConcept C95190672 @default.
• W4239529837 hasConcept C99454951 @default.
• W4239529837 hasConceptScore W4239529837C126322002 @default.
• W4239529837 hasConceptScore W4239529837C136764020 @default.
• W4239529837 hasConceptScore W4239529837C156957248 @default.
• W4239529837 hasConceptScore W4239529837C17744445 @default.
• W4239529837 hasConceptScore W4239529837C187212893 @default.
• W4239529837 hasConceptScore W4239529837C199539241 @default.
• W4239529837 hasConceptScore W4239529837C2776171842 @default.
• W4239529837 hasConceptScore W4239529837C2777625466 @default.
• W4239529837 hasConceptScore W4239529837C2777910003 @default.
• W4239529837 hasConceptScore W4239529837C2778335811 @default.
• W4239529837 hasConceptScore W4239529837C2779473830 @default.
• W4239529837 hasConceptScore W4239529837C2781049234 @default.
• W4239529837 hasConceptScore W4239529837C2908647359 @default.
• W4239529837 hasConceptScore W4239529837C41008148 @default.
• W4239529837 hasConceptScore W4239529837C535046627 @default.
• W4239529837 hasConceptScore W4239529837C71924100 @default.
• W4239529837 hasConceptScore W4239529837C71928629 @default.
• W4239529837 hasConceptScore W4239529837C95190672 @default.
• W4239529837 hasConceptScore W4239529837C99454951 @default.
• W4239529837 hasLocation W42395298371 @default.
• W4239529837 hasLocation W42395298372 @default.

• next